Heartseed Inc., a pioneering clinical-stage biotech company based in Tokyo, is at the forefront of developing groundbreaking treatments for severe heart conditions. Our cutting-edge approach involves utilizing stem cells to craft cardiomyocyte spheroids—tiny heart cell clusters. These clusters are surgically transplanted into the heart to enhance its functionality.

ITOCHU Chemical Frontier

SBI Group

SMBC Venture Capital

Sumitomo Mitsui Trust Investment

UTokyo Innovation Platform

Nissay Capital

Keio Innovation Initiative

Medical Incubator Japan

Medipal Holdings

Arcus Investment

Nikon-SBI Innovation Fund

KOEI TECMO CAPITAL

Sakano Atsushi

Heartseed Inc.

Heartseed Inc. CEO Keiichi Fukuda Wins Japanese Society for Regenerative Medicine "Achievement Award"
 
This distinguished award is presented to individuals who have made significant scientific, technological advances in the field of regenerative medicine, or have made notable contributions to the development of the Japanese Society for Regenerative Medicine　
 (JSRM). 
 
The award ceremony and lecture were held on March 21, 2024, at the 23rd Annual Meeting of the Japanese Society for Regenerative Medicine. Fukuda delivered a lecture on the basic research and clinical application of cardiac regenerative therapy, and the path towards implementation in society.
 
Since our establishment in 2015, it has been a great honor for Heartseed Inc. to support Fukuda's achievements, including the initiation of the Phase 1/2 clinical trial of allogeneic iPSC-derived cardiomyocyte spheroids, HS-001 in Japan (LAPiS trial). Heartseed Inc. will continue to lead innovations in the field of regenerative medicine.

Heartseed Inc. CEO Keiichi Fukuda was interviewed by Forbes Japan.
https://lnkd.in/gYxhT4md

Heartseed was selected by the Tokyo Metropolitan Government for the "Innovation TOKYO Project for the Future" in FY2021. Under this project, the Government subsidizes a portion of the expenses required to develop and improve products through open innovation with large companies. We appreciate the support of the Tokyo Metropolitan Government!


Exciting developments in regenerative medicine! Heartseed Inc.'s CEO, Dr. Keiichi Fukuda, delivered an inspiring keynote at Taichung Veterans General Hospital, Taiwan, showcasing our latest advances in cell therapy, including HS-001. This event underscores the growing collaboration between Japan and Taiwan in healthcare innovation.

We were honored by the warm reception from TCVGH's esteemed team, led by Superintendent Dr. Shih-Ann Chen, and the insightful tour of their facilities. This collaboration highlights our shared commitment to advancing medical science for global benefit.

Looking forward to more groundbreaking partnerships! 

https://lnkd.in/gAZbhUjV

#RegenerativeMedicine #CellTherapy #InternationalCollaboration #MedicalInnovation #Taiwan #Japan


Do you know some of the key biotech companies in Japan?🗾

Japan has one of the highest life expectancies in the world and with an aging population, the country is faced with the challenge of chronic conditions. Japan has an impressive pool of companies working on regenerative medicine and counts several interesting companies apart from industry landmarks Takeda Pharmaceuticals or Eisai.🧪

Here are 10 Japan-based biotech companies to know about!⬇️

https://lnkd.in/dGk965yR 

#japanesebiotech #biotechinjapan #lifesciencejapan #regenerativemedicine #TakedaPharmaceuticals #Eisai #biotechcompanies #japaneseinnovation 

Chordia Therapeutics Inc | Heartseed Inc. | LUCA Science Inc. | Modulus Discovery | Noile-Immune Biotech | Peptidream | RaQualia Pharma | Restore Vision |  SanBio | StemRIM

3月15日の再生医療EXPO大阪で、注目の再生医療ベンチャーとして、Heartseed Inc. CEOの福田恵一が講演します。

https://lnkd.in/gmz5Jt_t

Heartseed Inc. is a biotechnology company focused on developing innovative regenerative medicine therapies for heart disease. The company's mission is to contribute to the advancement of cardiac regenerative medicine through the development of cell-based therapeutics that aim to restore cardiac function in patients with severe heart failure.

JP:HEARTSEED

Heartseed Inc.

Filings Not Available